The Quality of Earnings report will not tell you whether your value creation plan is achievable, because that is not its job. A QofE answers one question: are the earnings real? It normalizes EBITDA, scrubs one-time items, tests revenue recognition, and confirms that the number you are underwriting actually exists. What it never tests is whether the number you are projecting can exist — whether this company, with these customers, this pricing power, this margin structure, and this management team, can deliver the growth your model requires at your entry multiple. That second question is operational, not accounting. And in a market where multiple expansion is dead and the entire return must be manufactured through earnings growth over a roughly six-year hold, it is the question that decides whether the deal works.
We have sat on both sides of this gap — as operators inheriting theses that diligence never tested, and as advisors running the tests before the wire transfer. The pattern is consistent: deals rarely fail because the historical earnings were fake. They fail because the projected earnings were never achievable, and nobody checked. This article lays out what operational validation actually examines, the four tests that fit inside a real deal window, and why every one of the three possible outcomes — validate, adjust, or walk — makes the sponsor money.
What Is the Difference Between a QofE and Operational Validation?
Think of the two as answering different tenses. The QofE is backward-looking: it audits what happened, adjusts for what should not recur, and produces a defensible baseline. Operational validation is forward-looking: it takes the sponsor’s value creation thesis — the specific claims in the model about price, mix, share, M&A, and cost — and pressure-tests each claim against the operational facts of the business. The QofE asks whether last year’s $20M of EBITDA was really $20M. Operational validation asks whether the $35M in year four of your model is a plan or a wish.
The two are complements, not substitutes, and neither replaces the other. A clean QofE with a broken thesis is a fully audited overpayment. A brilliant thesis on top of manufactured earnings is fraud with good strategy. Sponsors need both — but the market has industrialized the first and largely improvised the second. Every deal gets a QofE from a name-brand firm following a standard scope. Operational validation, where it happens at all, is often a partner’s gut feel, a few management meetings, and a consultant’s market study that says the industry is growing. None of that tests the thesis. It decorates it.
Why Do CIMs Make Operational Validation Harder, Not Easier?
Because a CIM is a marketing document engineered by professionals whose fee depends on the price. It is not lying, exactly — the numbers are usually accurate. It is curated. And the curation follows predictable patterns that a disciplined reader can reverse-engineer. Growth is presented at the segment level when the product level would show one aging SKU carrying everything. Customer concentration is disclosed as “no customer over 15% of revenue” while profit concentration — which is what actually matters — goes unmentioned, because the top quartile of customers typically generates 105% to 150% of total profit, and in troubled businesses the tail is quietly consuming the head. Price increases are called “realized” when they were announced; the gap between announced and realized pricing is one of the most reliable tells in any industrial CIM. Adjusted EBITDA walks upward through addbacks that each sound reasonable and collectively describe a different company.
The red flags worth training your team to spot are almost never in what the CIM says. They are in what it declines to break out: profit by customer, margin by product line, pricing realization versus announcement, revenue retention excluding the top three accounts, and management tenure below the CEO. When a CIM is silent on a metric the banker obviously has, the silence is the data.
What Can Actually Be Tested in a 3-6 Week Deal Window?
Everything above sounds fine in principle, and then the deal calendar arrives: exclusivity is signed, close is in five weeks, and the data room is a moving target. The standard objection to operational diligence is that there is no time. The objection fails because the four tests that matter do not require months — they require knowing exactly what to look for. Each test runs on data the seller already has, and together they fit inside three to six weeks, in parallel with the QofE, using the same data room plus two or three targeted management sessions.
- Test one: profit concentration. Rank every customer and every product by profit contribution, not revenue, and run the quartile math. In a healthy business the top quartile of customers produces 105% to 150% of total profit and the tail is manageable. What you are looking for is the shape of the tail: how much profit the bottom half destroys, whether the model’s growth assumptions depend on exactly the customers the data says to fire, and whether the top accounts are secured or drifting. This single analysis kills or confirms more theses than any other.
- Test two: the pricing corridor. Compare announced price increases to realized price by customer and product over the trailing three years. The gap between the two is the pricing corridor — the real, demonstrated room the company has to take price. If the model assumes 4% annual price and the corridor shows the company has never realized more than 1.5% without volume loss, the thesis has a hole exactly that size, and no QofE will ever find it.
- Test three: Right-to-Grow. Divide material margin by employee cost. A ratio around 2.0 means the business generates enough margin per payroll dollar to fund growth investment from its own operations; materially below that, every growth initiative in the model will be fighting the P&L for oxygen. This one ratio tells you whether the plan should lead with growth or must first fix the margin structure — and whether the year-one investments in the model are affordable or fictional.
- Test four: the Rule of Three team audit. Assess the top team against the three questions that predict execution: does each leader know the number, own a lever, and have a track record of delivering change rather than administering steady state? The model assumes a management team that can execute the thesis. Most deal teams assess this over dinner. A structured audit — role by role, against the actual demands of the plan — routinely finds that two or three of the seats the thesis depends on are occupied by people who cannot deliver it. Better to know at close, when the fix costs a search fee, than at month eighteen, when it costs a year.
Four tests, three to six weeks, run in parallel with the accounting workstream. The output is not a hundred-page report. It is a one-page verdict per test — confirmed, adjusted, or broken — with the evidence attached, delivered while the sponsor can still act on it.
Why Is Profit Concentration the First Test?
Because it is the fastest way to find out whether the business the CIM describes is the business that exists. Revenue concentration is a disclosed, managed, negotiated number. Profit concentration is usually unknown even to management. When the quartile analysis comes back showing that 30 customers generate 130% of profit and 400 customers destroy 30% of it, three things become clear at once: where the moat actually is, how much of the revenue base is ballast, and what 80/20 resourcing could unlock in the first year of ownership. Sometimes the analysis strengthens the deal — the concentration reveals a core franchise more valuable than the blended margins suggest, plus a tail that a disciplined owner can fix or shed. Sometimes it breaks the deal: the thesis assumed cross-selling into a long tail that turns out to be unprofitable at any volume. Either way, the sponsor learns it for a few weeks of analysis instead of two years of ownership.
What Does the Pricing Corridor Reveal That Market Studies Miss?
Market studies answer whether the industry can absorb price. The corridor answers whether this company can take it. Those are different questions, and the second one is the one the model is betting on. A company can operate in a perfectly rational industry and still have no pricing power because its contracts index to cost, its sales force discounts reflexively, or its two largest customers have audit rights on margin. The trailing-three-year comparison of announced versus realized price — by customer, by product — is the demonstrated fact pattern. It also produces something the market study never does: the specific list of where price is available. Which customers absorbed increases without pushback. Which products have realized price above the announcement, meaning the sales force is already finding room. That list is not just diligence — it is the first draft of the year-one pricing initiative, priced and sequenced before the deal closes.
What Does Right-to-Grow Tell You About the Plan’s Affordability?
Every value creation model contains growth investments — sales hires, capacity, product development — and almost none of them test whether the business can fund the investments while making the numbers. Right-to-Grow is that test. Material margin divided by employee cost, with roughly 2.0 as the line: above it, the business throws off enough margin per payroll dollar that growth spending is self-funding; below it, the P&L is too tight, and every investment dollar comes at the direct expense of reported EBITDA — which means the plan will quietly get cut the first time a quarter is missed. When the ratio comes back at 1.4, the honest conclusion is not that growth is impossible. It is that the plan must run in a different order: fix mix and price first, rebuild the ratio toward 2.0, then invest. Deals blow up not because that sequencing is unknowable, but because nobody ran the division problem before modeling year-one growth spend.
Why Audit the Team Before Close Instead of After?
Because the post-close timeline is brutal and the industry’s own base rate says so: roughly 70% of PE-backed CEOs are replaced during the hold, mostly in months 18 to 24 — which means the average sponsor spends a year and a half discovering what a structured audit finds in two weeks. The Rule of Three audit does not ask whether the executives are impressive. It asks whether each seat, against the specific demands of this thesis, is held by someone who knows the number, owns a lever, and has delivered change of this scale before. The output changes the deal in practical ways: the 100-day plan gets built around the seats that are strong, the search for the seats that are not starts before close instead of after the first missed quarter, and the sponsor prices the transition cost into the model rather than absorbing it as a surprise. Sometimes the audit surfaces the opposite — a second-layer operator the CIM never mentioned who should be running the company. That discovery alone can pay for the diligence.
Why Are All Three Outcomes — Validate, Adjust, Walk — Wins?
Operational validation ends in one of three verdicts, and the discipline only works if the sponsor genuinely accepts all three as good outcomes.
- Validate: the thesis survives contact with the data, and the sponsor closes with conviction instead of hope — plus a pre-built evidence base that makes the first board meeting a working session rather than a discovery session.
- Adjust: the thesis is directionally right but mispriced — the pricing corridor is narrower than modeled, or the team needs two hires the model did not fund — and the sponsor either retrades on evidence or reprices the plan internally. An adjustment found pre-close costs a negotiation; the same adjustment found at month twelve costs a year of the hold and usually a covenant conversation.
- Walk: the thesis is broken, and the sponsor declines to spend six years of fund life and partner attention proving it. Walking on evidence is not a failed process. It is the process working. The most expensive deals in any fund’s history are not the ones that got away — they are the ones that closed on a thesis nobody tested.
How Does Pre-Close Validation Pre-Write the 100-Day Plan?
Here is the compounding benefit that makes the economics of pre-close work undeniable: the diligence output and the 100-day plan are the same document at different resolutions. The profit concentration analysis becomes the 80/20 resourcing agenda — which customers get invested in, which get repriced, which get managed for cash. The pricing corridor becomes the year-one pricing initiative, already scoped to the customers and products where realization is demonstrably available. The Right-to-Grow math sets the sequence — growth first or margin first — and the investment budget the board locks. The team audit becomes the organization plan: who owns which lever, which searches start on day one, and who the successors are. Sponsors who skip pre-close validation spend the first hundred days doing this exact work — except now the clock is running, the management team is watching the new owner hesitate, and every week of analysis is a week not spent executing. Sponsors who run it walk in on day one with the number locked and the levers assigned. The first 100 days become command and control instead of orientation.
Should Validation Be a Deal-by-Deal Decision or a Standing Screen?
The sponsors who extract the most from operational validation stop treating it as something a deal team opts into and make it a standing screen across the pipeline — a stage-gate every deal passes before the IC votes, exactly like the QofE. The shift changes behavior upstream. Deal teams start asking sellers for profit-by-customer data earlier, because they know the screen will require it. Bankers who work with the fund repeatedly learn what the data requests will be and prep sellers accordingly. Theses get written more precisely, because the authors know each claim will be tested against a named analysis rather than debated in the abstract. And the fund builds a proprietary asset: a library of pricing corridors, concentration curves, and Right-to-Grow ratios across every business it has examined — including the ones it walked from — which sharpens every future underwrite. A single fund cycle of standing screens produces pattern recognition no market study can sell you.
This is the work our Deal & Thesis Validation engagement does: the four tests, run inside your deal window, in parallel with the QofE, ending in a validate-adjust-walk verdict and a pre-written first-hundred-days agenda for the deals that proceed. It is deliberately built to fit a three-to-six week exclusivity period, because that is the window in which the answer is still worth something. If you have a deal in the pipeline — or want the screen installed before the next one arrives — book a Sponsor Call and bring the thesis. We will tell you which claims in it have been tested, and which are still wishes wearing spreadsheets.
Frequently Asked Questions
What Is the Difference Between a Quality of Earnings Report and Operational Due Diligence?
A QofE is backward-looking accounting work: it confirms the historical earnings are real by normalizing EBITDA, scrubbing one-time items, and testing revenue recognition. Operational due diligence is forward-looking: it tests whether the value creation plan is achievable — whether the pricing, mix, share, and cost assumptions in the model can actually be delivered by this business and this team. The QofE validates the baseline; operational validation tests the thesis. Deals rarely fail because the history was fake. They fail because the projection was never achievable and nobody checked.
How Long Does Pre-Close Operational Diligence Take?
Three to six weeks, run in parallel with the QofE inside a standard exclusivity window. The four core tests — profit concentration by customer and product, the pricing corridor (announced versus realized price over three years), the Right-to-Grow ratio (material margin divided by employee cost, with roughly 2.0 as the benchmark), and a Rule of Three audit of the management team — all run on data the seller already has, plus two or three targeted management sessions.
What Are the Biggest Red Flags in a CIM?
The red flags are usually in what the CIM declines to break out rather than in what it says. Watch for growth shown at segment level but never at product level, revenue concentration disclosed while profit concentration goes unmentioned, price increases described as realized when they were merely announced, adjusted EBITDA built from addbacks that collectively describe a different company, and no visibility into management tenure below the CEO. When a CIM is silent on a metric the banker obviously has, the silence is the data.
What Happens If Operational Diligence Breaks the Deal Thesis?
That is the process working, not failing. Validation ends in one of three verdicts, and all three are wins: validate (close with conviction and a pre-built plan), adjust (retrade or reprice the plan on evidence, at negotiation cost instead of a lost year), or walk (decline to spend six years of fund life proving a broken thesis). The most expensive deals in any fund’s history are the ones that closed on an untested thesis — a walk on evidence is dramatically cheaper than a slow discovery during the hold.
Does Pre-Close Operational Diligence Replace the 100-Day Plan?
It pre-writes it. The profit concentration analysis becomes the 80/20 resourcing agenda, the pricing corridor becomes the scoped year-one pricing initiative, the Right-to-Grow math sets the investment sequence and budget, and the team audit becomes the organization plan with searches already started. Sponsors who skip validation spend their first hundred days doing this same work while the clock runs; sponsors who run it pre-close start day one with the number locked and the levers assigned.